bioAffinity Technologies, Inc. (BIAF)

2.0100 -0.0300 (-1.47%) As of 11:28AM EDT. Market open.

bioAffinity Technologies, Inc.

22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Steven Girgenti	Founder & Executive Chairman of the Board	113.75k	N/A	1946
Ms. Maria Zannes J.D.	Founder, President, CEO & Director	299.17k	N/A	1956
Mr. Michael Dougherty CPA, M.B.A.	VP & CFO	238.92k	N/A	1979
Mr. Xavier T. Reveles M.S.	Chief Operating Officer	N/A	N/A	1970
Dr. Vivienne I. Rebel M.D., Ph.D.	Executive VP and Chief Medical & Science Officer	238.39k	N/A	1966
Mr. Timothy P. Zannes J.D.	Executive VP, Secretary & General Counsel	N/A	N/A	1953
Ms. Julie Anne Overton	Director of Communications	N/A	N/A	N/A
Mr. Dallas J. Coleman	National Director of Sales	N/A	N/A	N/A
Dr. William Bauta Ph.D.	Senior Vice President of Therapeutics	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

Corporate governance

bioAffinity Technologies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.